IL31 and Alzheimer disease: However, AEs such as AD exacerbation and non-specific edematous erythema have been observed in over 10–20% of patients following nemolizumab treatment [55], suggesting that IL-31 inhibition may not exert uniformly anti-inflammatory effects.